Using MRI to Improve Surgery Selection for Pancreatic Cancer Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the added value of magnetic resonance imaging (MRI) alongside computed tomography (CT) in the diagnostic assessment of pancreatic cancer patients. It will be a nationwide, prospective clinical trial focusing on the identification of liver metastases in patients deemed potentially resectable. By comparing the diagnostic outcomes of MRI and CT, the study seeks to enhance the decision-making process for surgical interventions in pancreatic cancer cases.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Pancreatic cancer patients considered to have a locally resectable or borderline resectable tumor by the local hepato-pancreato-biliary multidisciplinary team board
* No liver metastases on CT
* At least 18 years old and able to provide informed consent
* Expected pancreatic ductal adenocarcinoma based on CT scan

Exclusion criteria:

* Metastatic disease
* Prior receipt of neoadjuvant chemotherapy or downstaging/-sizing treatment
* Comorbidity rendering major surgery unfeasible (inoperable)
* No informed consent
* Unable to undergo MRI (Kidney insufficiency (eGFR \< 60 ml/min/1.73 m2 body surface ar-ea); Claustrophobia; Cardiac pacemaker)
* Postoperative histology other than adenocarcinoma of pancreato-biliary origin.
* MRI with liver-specific contrast performed during standard workup.

Where it's running

• Aalborg University Hospital
  Aalborg, Denmark Recruiting
• Aarhus University Hospital
  Aarhus, Denmark Recruiting
• Rigshospitalet
  Copenhagen, Denmark Recruiting

Study contacts

• Principal investigator: Jakob Kirkegård, MD, PhD — Aarhus University Hospital
• Study coordinator: Jakob Kirkegård, MD, PhD
• Email: jakob.kirkegaard@auh.rm.dk
• Phone: +4522900604

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Screening for pancreatic cancer in high-risk individuals

  This study is testing if combining blood tests and symptom checks with regular screenings can help find pancreatic cancer earlier in people who are at higher risk because of their genetics.

  Recruiting Early Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06122896

• Evaluating the impact of MR-guided radiation therapy on cancer treatment outcomes

  This study is testing how using a special type of radiation therapy with real-time imaging can improve treatment results and quality of life for adults with cancer.

  Recruiting at 14 sites UMC Utrecht · Pittsburgh, Pennsylvania and 17 other locations · NCT04075305

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery

  This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.

  Recruiting Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07910383

• Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer

  This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07895498

• Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer

  This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.

  Recruiting Ningbo Medical Center Lihuili Hospital · Ningbo, Zhejiang · NCT07892573

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.